A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.

Mark C Markowski Ronald Tutrone Christopher M PieczonkaK Gary BarnetteRobert H GetzenbergDomingo RodriguezMitchell S SteinerDaniel R SaltzsteinMario A EisenbergerEmmanuel S Antonarakis

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

This clinical trial demonstrated that chronic oral daily dosing of sabizabulin has a favorable safety profile with preliminary antitumor activity. These data support the ongoing phase III VERACITY trial of sabizabulin in men with mCRPC.

Keyphrases

phase iii
clinical trial
open label
phase ii
double blind
placebo controlled
middle aged
squamous cell carcinoma
study protocol
electronic health record
randomized controlled trial
big data
machine learning
artificial intelligence